A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN), are rare but life-threatening cutaneous adverse reactions to drugs, especially to allopurinol, carbamazepine, lamotrigine, phenobarbital, phenytoine, sulfamethoxazole, oxicam and nevirapine. Recently, a strong association between carbamazepine and allopurinol induced SJS or TEN has been described with respectively, HLA-B*1502 and HLA-B*5801 in a Han Chinese population from Taiwan and other Asian countries. OBJECTIVE: The objective is to further investigate the relationship between SJS/TEN and HLA-B in a large number of patients in a European population. METHODS: HLA-B genotyping was performed on 150 patients included in a European study (RegiSCAR) of SJS and TEN. We focused on patients related to 'high-risk' drugs including: 31 cases related to allopurinol, 28 to sulfamethoxazole, 19 to lamotrigine and 14 to oxicam. RESULTS: Sixty-one percent of 31 allopurinol-induced SJS/TEN patients carried the HLA-B*5801 allele and the figure was 55% for 27 patients of European ancestry [odds ratio=80 (34-187)], (P<10(-6)) as previously observed in Han Chinese. For other drugs, two rare alleles showed a weaker association with SJS/TEN in a limited number of patients: B*38 for sulfamethoxazole or lamotrigine-related patients, and B*73 for oxicam. CONCLUSION: At variance with prior results in Asia, this study shows that even when HLA-B alleles behave as strong risk factors, as for allopurinol, they are neither sufficient nor necessary to explain the disease. Further investigations are necessary to delineate the exact role of the HLA region in SJS/TEN, and to look for other associations in other regions of the genome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807 · cited 1×
“Adverse reactions to drugs are important causes of morbidity and even of death in developed countries [ 1 ].”
BackgroundA marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Self-citationMallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380 · cited 1×
“In the previous years growing interest focused on the role of HLA in severe drug reactions, which was initiated by the demonstration that HLA-B*5701, was strongly associated with hypersensitivity to the anti-HIV medication abacavir [ 16 ,17].”
BackgroundHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284 · cited 4×
“In Taiwan the carrier prevalence of B*5801 was 20% in a control group [ 21 ].”
BackgroundInfluentialMockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Self-citationInhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005 · cited 1×
“The initial events triggering the immune reaction remain to be identified [ 10 ].”
BackgroundInhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 807
Delayed Drug Hypersensitivity Reactions
Pichler, W. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00012 · Cited by 735
Cited by
Items 601–660 of 660
Pharmacogenomics in Therapeutics
Kaushal, S. (2009)
Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in
Yang, F., Yang, Y., Zhu, Q., Chen, S., Fu, X., Yan, S., Meng, C., Ma, L., Xu, J., Luo, X., et al. (2015)
FROM PATHOLOGICAL PROCESSES TO PATHOGENESIS OF MEdICALLY ALLERGY
Mavlyanov, I. R., Хамидович, А. А., & Искандарович, М. З. (2017) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov20179219-27
Urate–lowering therapy: xanthine oxidase inhibitors
Stamp, L. K. (2013) · doi:10.2217/ebo.12.197
Cutaneous Drug Reactions With Systemic Features
Knowles, S. R., Shapiro, L. E., & Shear, N. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-61211-1.00067-x
Stevens-Johnson Syndrome and Its Manifestation in Oral Cavity
Vokurka, J., Fassmann, A., Zgažarová, S., Augustín, P., Hollá, L. I., & Vaněk, J. (2010) · Česká stomatologie a praktické zubní lékařství · doi:10.51479/cspzl.2010.032
Doña, I., Jurado‐Escobar, R., Pérez‐Sánchez, N., Laguna, J. J., Bartra, J., Testera‐Montes, A., María, R. S. D. S., Torres, M. J., & Cornejo-García, J. A. (2021) · Current Treatment Options in Allergy · doi:10.1007/s40521-020-00278-4
Progress in study on the association between HLA genetic variation and adverse drug reactions.
Liu, Y., Zeng, X., & Ouyang, D. (2021) · PubMed Central · doi:10.11817/j.issn.1672-7347.2021.200256
Phương, N. T. T., Hoi, N. T., & Shin, J. (2021) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-030-75506-5_47
Pimenta, M. M. G. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/mxeq-wg04
Mockenhaupt, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82804-2_38
Self-citationPhung, T. L., Wright, T. S., Pourciau, C. Y., & Smoller, B. R. (2017) · Springer eBooks · doi:10.1007/978-3-319-44824-4_4
Pharmacogenetics to Avoid Adverse Drug Reactions
López-Fernández, L. A. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-3343-8
Knowles, S. R., & Shear, N. H. (2014) · Wiley eBooks · doi:10.1002/9781118357606.ch47
Cunningham, M. L. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13664958.15067080
Tu, C. D., Chung, W., Chen, S., & Chen, Y.-T. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-283-4_13
Diagnosis and Management of DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) Syndrome
Lee, S. (2022) · Journal of Pharmacoepidemiology and Risk Management · doi:10.56142/2022.14.1.29
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis- An OverviewPreprint
Garg, V. K. (2022) · Preprints.org · doi:10.20944/preprints202210.0270.v1
Mechanisms of Drug Hypersensitivity
Chang, C., Chen, C., & Chung, W. (2022) · Updates in clinical dermatology · doi:10.1007/978-3-031-09388-3_2
Lebrun‐Vignes, B. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-77570-3.00011-0
Dobrianskyi, D. V., Tarchenko, I. P., Гуменюк, Г. Л., Dorokhova, А. О., Kozhevnikova, К. О., & Zavatska, А. І. (2022) · Asthma and allergy · doi:10.31655/2307-3373-2022-4-23-30
Systemische Medikamenteneinnahme und ihr potenzieller Einfluss auf die orale Gesundheit
Jackowski, J., & Benz, K. (2023) · wissen kompakt · doi:10.1007/s11838-023-00175-x
Savoir prescrire l'allopurinol
Bardin, T., & Richette, P. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-78249-7.00020-5
Drug hypersensitivity linked to genetic variations of human leukocyte antigen
Guin, D., & Kukreti, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18649-3.00018-5
Okuläre Beteiligung bei Stevens-Johnson-Syndrom (SJS) und Toxisch epidermaler Nekrolyse (TEN)
Chronopoulos, A., Mockenhaupt, M., & Pleyer, U. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-65929-8_121-1
Self-citationDermatological discovery: the frontiers between genetics, pharmacology and the patient
Walsh, S. (2009) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/1478271520093904028
Charsouei, S., Farid, S. S., Nourollahi, T., Asgharvand-Hajeb, A., Tutunchi, K., Sadeghi‐Hokmabadi, E., Abolhasani, S., Azar, H., Hamzehzadeh, S., Ahmadi, B., et al. (2025) · Biomedicine Advances · doi:10.34172/bma.16
“20, 21 In a study conducted on the recommendation of the US Food and Drug Administration, the prevalence of the HLA-B*1502 allele was reported to be high in the Chinese and East Asian populations.”
Okuläre Beteiligung bei Stevens-Johnson-Syndrom (SJS) und Toxisch epidermaler Nekrolyse (TEN)
Chronopoulos, A., Mockenhaupt, M., & Pleyer, U. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65823-9_121
Self-citationGenomic Biomarkers Associated with the Risk of Sulfasalazine-Induced Drug Eruptions
Fukunaga, K., & Mushiroda, T. (2025) · Major Histocompatibility Complex · doi:10.12667/mhc.32.37
พิมน้ำเย็น, น. (n.d.) · Disease Control Journal · doi:10.14456/dcj.2019.20
Limkobpaiboon, S. (2009) · NRCT Data Center · doi:10.14457/cu.the.2009.1734
Chou, W.-H., Chen, L.-C., Wong, H. S.-C., Chao, C.-H., Chu, H.-W., & Chang, W.-C. (2024) · Figshare · doi:10.6084/m9.figshare.25749909
Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: PERL Allopurinoal Study
Hasnain, D. M. A., Anwar, D. Z., & Rehman, D. A. (2020) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.4260638
Chou, W.-H., Chen, L.-C., Wong, H. S.-C., Chao, C.-H., Chu, H.-W., & Chang, W.-C. (2024) · Figshare · doi:10.6084/m9.figshare.25750093
Η γενετική βάση των επαγομένων από τα φάρμακα δερματικών επιπλοκών
Gerogianni, K. (2017) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.3981
Chou, W.-H., Chen, L.-C., Wong, H. S.-C., Chao, C.-H., Chu, H.-W., & Chang, W.-C. (2024) · Figshare · doi:10.6084/m9.figshare.26715535
ตัวบ่งชี้ทางเภสัชพันธุศาสตร์เพื่อการทำนายอาการผื่นแพ้ยา
สุขเกษม, ช. (2009) · Thai Pharmaceutical and Health Science Journal - วารสารไทยเภสัชศาสตร์และวิทยาการสุขภาพ
Allopurinol: Risk Stratification and Safe Prescription
Shah, C., & Gornes, C. (2024) · eScholarship (California Digital Library)
Araújo, M. A. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Leisinger, S. (2009) · FreiDok plus (Universitätsbibliothek Freiburg)
Saini, J. P. S., Thakur, A., & Yadav, D. (2026) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgag001
Kosanlawit, J., Konyoung, P., Amornpinyo, W., Tassaneeyakul, W., Kanjanawart, S., Pattanacheewapull, O., Purimart, D., & Nakkam, N. (2026) · Medical Sciences · doi:10.3390/medsci14010098
“For example, a study by Lonjou et al. [15] identified a strong association between HLA-B*73:01 and oxicam-induced SJS/TEN.”
Allopurinol-Related Severe Cutaneous Adverse Reactions: A Narrative Review
Cipolletta, E., Mahil, S. K., Smith, C. H., & Abhishek, A. (2026) · Gout Urate and Crystal Deposition Disease · doi:10.3390/gucdd4010005
“Many studies have reported an association of certain HLA haplotypes such as HLA-B*58:01 with an increased risk of SJS/TEN among allopurinol initiators [48–50].”
Lee, H. K., Kang, M. J., Kim, H., Jang, H. Y., Han, N., Kim, I.-W., & Oh, J. M. (2026) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000596
Mathieu, O. (2010) · theses.fr (ABES) · doi:10.70675/a19a62ebzcc9az4457zb4f7z450c0107429d
Évaluation du terrain génétique des hypersensibilités
Bursztejn, A. ‐. (2013) · theses.fr (ABES) · doi:10.70675/f2d9f47bz8b72z454fzac9ez8c078999793c
Rôle des lymphocytes T CD8+ dans les hypersensibilités retardées cutanées médicamenteuses
Villani, A. P. (2019) · theses.fr (ABES) · doi:10.70675/0c979a0ez843cz4002zabcczdf942e54dc18
Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): Immunologic Reactions
Rajendran, S., & Zimmerman, D. E. (2026) · Springer eBooks · doi:10.1007/978-3-319-74698-2_195-2
Howell, W. M. (2026) · International Journal of Immunogenetics · doi:10.1111/iji.70052
HLA-B alleles confer susceptibility to sulfasalazine-induced severe cutaneous adverse reactions
Wang, C., Chen, W., Chen, C., Chu, C., Hui, R. C., Lu, C., Chiu, T., Hung, S. I., Huei, H. Y., Tassaneeyakul, W., et al. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.04.017
Réactions cutanées auxmédicaments
Bettuzzi, T., Lebrun‐Vignes, B., Oro, S., Assier, H., & Chosidow, O. (2026) · Elsevier eBooks · doi:10.1016/b978-2-294-77608-3.00020-x
Bettuzzi, T., & Lebrun‐Vignes, B. (2026) · Therapies · doi:10.1016/j.therap.2026.08.001
Análise populacional dos alelos no antígeno leucocitário humano (HLA) de importância farmacogenômica
Morgão, W. R. (2024) · Lume (Universidade Federal do Rio Grande do Sul)
Dzhemileva, L. U., D'yakonov, V. A., Marshala, S. N., Хуснутдинова, Э. К., Deviatkin, A. A., & Shipulin, G. A. (2026) · Medical Sciences · doi:10.3390/medsci14060612
“…within highly homogeneous East Asian cohorts, and comprehensive mapping shows that specific combinations of alternative major histocompatibility alleles (such as HLA-B*58:02 , HLA-A*34:02 , and HLA-B*35:01 ) are present in 100% of allopurinol-induced SCAR cases within Caucasian subsets [124].”
Toxidermie à l’Allopurinol : Vigilance à la Prescription !
Bonkoungou, M., Kaboré, F., Tiendrébogo, W. J. S., Ouedraogo, D.-D., Niamba, A. P., & Traoré, A. (2020) · HEALTH SCIENCES AND DISEASE · doi:10.5281/hsd.v22i1.2476
Sahawatwong, S., & Rajatanavin, N. (2026) · Thai Journal of Dermatology
Li, Y. (n.d.) · Murdoch University Research Portal
Dashti, M., Al-Matrouk, A., Channanath, A., Hebbar, P., Al-Mulla, F., & Thanaraj, T. A. (2022) · doi:10.3389/fphar.2022.891838.s004
Metadata
- Authors
- Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., Schumacher, M., Roujeau, J.-C., Hovnanian, A., & Mockenhaupt, M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- University Medical Center Freiburg (DE)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Ben-Gurion University of the Negev (IL)
- University of Milan (IT)
- Leiden University Medical Center (NL)
- Innsbruck Medical University (AT)
- Université Paris-Est Créteil (FR)
- Corresponding author
- Roujeau, Jean-Claude
- Venue
- Pharmacogenetics and Genomics
- Published
- 2008-02
- Volume
- 18
- Issue
- 2
- Pages
- 99-107
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2025161685
- Cited by
- 624
- References
- 28
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 23 · 2023: 26 · 2022: 29 · 2021: 34 · 2020: 23 · 2019: 31 · 2018: 36 · 2017: 40 · 2016: 26 · 2015: 48 · 2014: 43 · 2013: 43 · 2012: 40
- FWCI
- 33.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- Stevens-Johnson syndrome, toxic epidermal necrolysis, HLA-B*58:01, HLA-B*15:02, allopurinol, sulfamethoxazole, lamotrigine, oxicams, drug-induced skin reaction, European populations, genetic susceptibility
- MeSH terms
- Adult, Aged, Base Sequence, Female, Humans, Male, Middle Aged, Stevens-Johnson Syndrome, HLA-B Antigens, DNA Primers, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.